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Helicobacter pylori infection shows a worldwide prevalence of around 50%. However, only a minority of infected individuals
develop clinical symptoms or diseases. The presence of H. pylori virulence factors, such as CagA and VacA, has been
associated with disease development, but assessment of virulence factor presence requires gastric biopsies. Here, we evaluate
the H. pylori recomLine test for risk stratiﬁcation of infected patients by comparing the test score and immune recognition of
type I or type II strains deﬁned by the virulence factors CagA, VacA, GroEL, UreA, HcpC, and gGT with patient’s disease
status according to histology. Moreover, the immune responses of eradicated individuals from two diﬀerent populations were
analysed. Their immune response frequencies and intensities against all antigens except CagA declined below the detection
limit. CagA was particularly long lasting in both independent populations. An isolated CagA band often represents past
eradication with a likelihood of 88.7%. In addition, a high recomLine score was signiﬁcantly associated with high-grade
gastritis, atrophy, intestinal metaplasia, and gastric cancer. Thus, the recomLine is a sensitive and speciﬁc noninvasive test for
detecting serum responses against H. pylori in actively infected and eradicated individuals. Moreover, it allows stratifying
patients according to their disease state.
1. Introduction
H. pylori is a common and widespread bacterial pathogen
that infects more than half of the world’s population [1].
H. pylori colonizes the human stomach and always leads
to the development of an active gastritis [2], which in
the majority of cases remains asymptomatic. Chronic gas-
tritis may, however, lead to the development of several
gastrointestinal diseases such as chronic atrophic gastritis
[3], duodenal and gastric ulcers [4], in 1-2% to the
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development of gastric cancer [5, 6], and lymphoma [7, 8].
Especially, patients with the so-called corpus dominant
severe gastritis are at risk for gastric cancer, as severe gastric
inﬂammation can lead to atrophy, metaplasia, dysplasia, and
ﬁnally, gastric cancer [9]. More than 90% of all gastric cancer
cases are associated with a chronic H. pylori infection [10]
and lead to more than 700,000 stomach cancer-related deaths
per year worldwide [11]. Thus, gastric cancer remains the
third leading cause of cancer-related mortality [12]. Studies
have shown that eradication therapy of H. pylori can prevent
gastric cancer development [13, 14]. Due to the high number
of infected individuals, it is necessary to identify patients
at increased risk for gastroduodenal disease in order to
subject them to preventive eradication therapy. A number
of methods for the detection of H. pylori are currently
available: histological analysis, microbial culture, and urease
breath test are most commonly used. However, the ﬁrst two
diagnostic methods require upper gastrointestinal endoscopy
in order to obtain biopsy specimens for testing. None of the
aforementioned methods is able to predict the outcome of
an H. pylori infection in terms of malignant or benign
outcome. The line assay system (Helicobacter recomLine)
analyses immunoglobulin G (IgG) antibody responses to six
H. pylori antigens (CagA, VacA, GroEL, UreA, HcpC, and
gGT), some of which are already known to be linked to a
higher risk of disease, as for instance the antigens CagA,
VacA, and GroEL [15–17]. The recomLine diﬀerentiates the
more virulent type I H. pylori immune response (CagA
and/or VacA positive) and the less pathogenic type II
immune response (CagA/VacA negative). As the severity of
inﬂammation, and thus immune response, correlates with
the risk for gastric cancer [9], the recomLine may have pre-
dictive properties, which we aimed at evaluating in the
present study. We validated the performance of the recom-
Line test compared to histology as a gold standard, with
particular focus on the correlation between the recomLine
test results and chronicity/activity of inﬂammation as well
as most severe lesions according to histology.
As eradication of H. pylori has become quite common,
tests were developed to conﬁrm treatment success. The
Maastricht guidelines consider the urea breath test adequate
to conﬁrm successful treatment four weeks after eradication
therapy [18]. Antibody responses towards antigens usually
sustain for a long period after eradication therapy, as previ-
ously shown [19–22]. These studies suggest that serology
was not applicable for eradication control. However, while
some immune responses to certain antigens persist for
decades (especially CagA), antibody titres against other
antigens decrease within a shorter period, also depending
on the Ig-class tested [23]. This phenomenon could also
be utilized as readout to conﬁrm treatment success by ana-
lysing the decline of antibody responses, as shown before
[24]. Wang et al. conclude from their study that it would
be the reasonable and even perhaps preferred method of
monitoring H. pylori infections [25]. In order to get a
better insight into posttreatment IgG immune responses,
we analysed sera of a subgroup of patients that had under-
gone documented eradication therapy by applying the
recomLine assay.
2. Methods
2.1. Study Populations and Histology. The analysis was based
on a study population recruited between October 2010 and
February 2012 by two gastroenterological practitioners in
Munich and Bayreuth (Germany). Patients receiving active
immunosuppressive therapy, showing coagulation defects,
or suﬀering from malignant diseases were excluded from
the study. Serum samples and gastric biopsies of the antrum
and corpus were obtained from patients with upper abdom-
inal complaints who underwent gastroscopy after informed
consent. The serum samples were stored at −20°C until
testing for IgG antibodies against H. pylori. For all partic-
ipants included, age, gender, medical history, and histology
status were recorded. H. pylori status was deﬁned via his-
tology performed at the Institute of Pathology, Klinikum
Bayreuth, or the Institute of Pathology at the Technische
Universität München. Therefore, biopsies were ﬁxed in 4%
neutral buﬀered formalin, dehydrated in a series of increasing
alcohols and xylene, embedded in paraﬃn, serially sectioned,
deparaﬃnized, and stained. All biopsies were stained rou-
tinely with H&E and immunohistochemical detection of for
H. pylori at the Institute of Pathology, Klinikum Bayreuth,
using Roche monoclonal antibody clone SP48 rabbit-anti-
human 790-1014 on Ventana Benchmark Ultra, Strassbourg,
France. Pathological evaluation of tissue samples was done
according to the updated Sydney System [26]. The chronicity
of inﬂammation was scored by the mucosal inﬁltration with
lymphocytes and plasma cells. The activity of inﬂammation
was scored based on the number of neutrophilic granulocytes
within the tunica propria. Both parameters are indicated as
mild, moderate, and severe. Apart from chronicity and
activity of inﬂammation, other pathological ﬁndings such as
atrophy, metaplasia, dysplasia, ulcer, and carcinoma were
recorded. For statistical analysis, these were grouped as most
severe lesions. No gastric lymphomas were detected in the
present study cohort.
Eradicated cases were deﬁned either through histology
(Ex-H. pylori gastritis) or by documentation of the attending
gastroenterologist. The time since eradication was either
deﬁned by a known date of eradication (submitted by the
gastroenterologist) or determined according to the last date
of H. pylori positivity in histology, which was followed by
eradication therapy and resulted in an Ex-H. pylori gastritis
in histology or a negative histological result, conﬁrming the
success of eradication. In addition, a Dutch cohort was tested
prospectively with the recomLine not knowing current H.
pylori status. The study was approved by the ethics commit-
tee of the Technische Universität München (May 20, 2009).
2.2. The recomLine Serologic Assay System. The recomLine is
based on six recombinant antigens: CagA, VacA, GroEL,
UreA, HcpC, and gGT, which are immobilized on a nitro-
cellulose. On every test strip, a reaction control, antibody
control, and cutoﬀ control band are included. For test
quantiﬁcation, the scanner OpticPro S28 (Plustek, Korea)
and recomScan software (Mikrogen, Germany) were used
according to the manufacturer’s instructions. The developed
test strips were digitalized by scanning, and the band patterns
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were assessed via a deﬁned algorithm. The band intensities
were determined in more than 750 grey levels and are given
in arbitrary units (AU). The recomLine antigens CagA,
VacA, and GroEL were scored with two points each, and
the other antigens with one point each, adding up to a
maximum score of nine points. Results with one point were
categorized as borderline and two or more points were con-
sidered positive. Representative images of ﬁve recomLine
tests are shown in Supplementary Figure 1 available online
at https://doi.org/10.1155/2017/8394593. Detailed informa-
tion and description on the development of the recomLine
has been published earlier [27].
2.3. Statistical Analysis. Statistical analysis was performed as
described before [27]. The performance of the recomLine
was validated against histological assessment as gold stan-
dard calculating the sensitivity and speciﬁcity. The immune
response frequency was calculated comparing the ratio
between patients positive for a certain antigen and the total
number of individuals tested positive. The test results for H.
pylori positive and negative patients analysed with the recom-
Line were validated against histology results. Diﬀerences in
the study population were assessed using Pearson’s χ2 test
(c2) or the nonparametric Kruskal-Wallis test (H). Mean
single values were compared using the two-tailed t-test with
95% CIs (t). Signiﬁcances in mean band intensity were
calculated using the one-way ANOVA (F). The p values were
depicted in the ﬁgure legends as follows: letters indicating the
test used, number/numbers in parentheses indicating the
degree(s) of freedom, and followed by the deﬁned statistics
value and the signiﬁcance level. Diﬀerences were rated as
signiﬁcant at p < 0 05.
3. Results
3.1. Patient Population and Performance of recomLine Assay.
The German cohort of 1291 patients is characterized as
follows: 447 (34.6%) patients were H. pylori negative and
409 (31.7%) patients were H. pylori positive according to
histology. The negative population was included to deter-
mine the basic test performance values (sensitivity and
speciﬁcity) [27]. As this manuscript focuses on the serologi-
cal response of the H. pylori positive and eradicated patients,
more detailed information on the H. pylori negative patients
are not presented. 435 (33.7%) patients had previously
undergone H. pylori eradication treatment. The cumulative
(past and present) prevalence of H. pylori in the study popu-
lation was 65.4% and increased with age.H. pylori-eradicated
patients were signiﬁcantly (p < 0 01) older than H. pylori
negative patients. The mean age was 53.6± 16.2 ranging from
18 to 89 years. In total, more female patients (708, 54.8%)
were included in the study. Detailed information on the study
populations analysed can be found in the Supplementary
Table 1. The performance values previously determined for
the recomLine assay [27] were conﬁrmed in this extended
population, as shown in Supplementary Table 2.
3.2. Eradicated Patients Frequently Show Only a CagA
Antibody Response. In order to assess (i) how serologic
responses to individual antigens changes over time and
(ii) if the serological response to individual antigens might
have the capacity to diﬀerentiate H. pylori infection pre-
or posttreatment, we investigated the immune response
patterns of a subgroup of individuals that had received
antibiotic treatment in the past.
Of all the individuals categorised as eradicated, detailed
information on eradication was known for 64.6% (281/435).
In total, 74.7% (210/281) of individuals with documented
eradication were recomLine positive. Moreover, a negative
correlation between the time since eradication and a positive
test result was observed (Figure 1(a)). The overall recomLine
positivity rates decreased from 79.0% at 0–5 years after
eradication therapy to 61.8% 12–17 years after therapy. This
negative correlation could also be observed analysing the
mean recomLine score (Figure 1(b)).
Besides the decrease of the total number of positive cases,
we also analysed the decrease of serologic response on a
single antigen level. Figure 1(c) shows the relationship
between the time since eradication therapy and the sero-
logical response to the antigens on the recomLine com-
pared to individuals with an active ongoing H. pylori
infection. Noteworthy, the antibody response against all
antigens decreased over time except for the CagA response
that was particularly long lasting (Supplementary Figure 2).
This can be explained by the mean band intensities as shown
in Figure 1(d). A decrease in mean serological signal was
shown for all antigens tested. However, a signiﬁcant decrease
was demonstrated for CagA (p < 0 01), VacA (p < 0 01),
GroEL (p < 0 01), HcpC (p < 0 01), and gGT (p < 0 01). The
mean CagA seroresponse intensity decreased by 43.3%
(117/271AU) over time but compared to the other antigens
still showed a signiﬁcantly higher (p < 0 01) mean band
intensity above cutoﬀ in the group of 12–17 years after
eradication as indicated in Figure 1(d). The signals for the
other antigens decrease to or below detection limit six years
after eradication, which explains the high isolated CagA
positivity rates (only positive for CagA) for this group. Con-
cerning the relative positivity of CagA, we observed that
CagA was signiﬁcantly (p < 0 01) more often positive in
eradicated patients (86.3%) than inH. pylori positive patients
with 69.2% positivity (Supplementary Figure 2). Moreover,
43.3% (91/210) of all recomLine positive cases in the
eradicated cohort showed an isolated CagA seroresponse,
compared to 5.5% (22/400) in the group with an ongoing
H. pylori infection. Comparing these two groups, the proba-
bility that a patient showing an isolated CagA band had been
treated in the past is 88.7% 0 433/ 0 433 + 0 055 ∗100 .
In order to substantiate this ﬁnding, we analysed a Dutch
cohort in which the H. pylori status was blinded. We initially
observed that in this cohort, the mean recomLine score
was signiﬁcantly (t(595) = 13.0, p < 0 001) lower (2.5± 2.3)
compared to the score of positive cases in the German
cohort (4.8± 1.9). Upon unblinding, it was conﬁrmed that
84.6% (193/228) of the individuals tested turned out to be
H. pylori negative by histology. Analysing the individuals
with documented eradication (n = 65) in more detail, the
antigen frequency in this population showed the same
pattern as observed in the German population, deﬁned by
3Journal of Immunology Research
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Figure 1: recomLine test results from patients without and with eradication therapy. (a) recomLine positivity, (b) mean recomLine
score, (c) immune response frequency, and (d) mean immune response intensity of individuals with an active ongoing H. pylori
infection (nHp positive = 402) compared to individuals having received antibiotic treatment in the past (nyears since eradication = 210), indicated as
years since eradication and grouped (0–5, 6–11, and 12–17 years) analysing a German cohort (DE). Moreover, the relationship between
(e) immune response frequency to individual antigens (●CagA, ■VacA, ▲GroEL, ▼UreA, ♦HcpC, and ○gGT) and (f) percentage of
isolated CagA immune response and the time since eradication therapy analysing a Dutch cohort (NL) (n = 65). While the immune response
for all antigens tested declines after eradication, the response towards CagA antibodies persists over a long period, resulting in an isolated
CagA positivity, which remains above cutoﬀ and is signiﬁcantly increased (p < 0 01) in the 12–17 years group compared to all other antigens.
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markedly lower antibody responses after eradication except
for the antibody response towards CagA (Figure 1(e)). As
shown in Figure 1(f), depending on the eradication time
point, the sensitivity to detect an individual with an isolated
CagA immune response in this population increases up to
100% after 15 years. Based on these results, the serological
response pattern showing an isolated CagA band might be
used to discriminate H. pylori positive from eradicated
patients when using this serology assay.
3.3. recomLine Results Correlate with Histological Findings
in H. pylori Positive Patients. To examine the relationship
between the recomLine test results and histological ﬁndings,
we focused on the cases which are positive by histology.
Of all the histologically positive cases, 98.3% (400/407)
were recomLine positive, with the majority of cases being
either CagA and/or GroEL positive. Hence, the serological
response to the antigens VacA, UreA, and gGT or their
combination was important to detect those cases that were
CagA andGroEL negative.Moreover, the additional informa-
tion gained from recognition of these antigens was valuable
for the identiﬁcation of patients with severe chronic and
active gastritis as these antigens also have an impact on the
overall score. As shown in Figure 2 compared to the number
of recognized antigens, the mean recomLine score signiﬁ-
cantly correlates with the chronicity (p < 0 01) and activity
(p = 0 032) of inﬂammation. Furthermore, the recomLine
score signiﬁcantly correlates (p = 0 019) with pathologic
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Figure 2: Box plot diagrams showing the association between recomLine test results (dark grey: score recomLine/light grey: number of
positive antigens) and histological ﬁndings in H. pylori positive cases. (a) Correlation between recomLine test results and the chronicity of
inﬂammation (n = 391). (b) Correlation according to the activity of inﬂammation (n = 389) as well as (c) pathological ﬁndings (n = 95)
according to histology. Data are presented as box plot showing the median, 75th and 25th percentile, outlier, and extreme values.
Signiﬁcances were calculated using the Kruskal-Wallis test. The results show a signiﬁcant correlation between the achieved recomLine
score and histological ﬁndings. The sum of positive antigens only correlates signiﬁcantly with the chronicity of inﬂammation.
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ﬁndings, which were grouped as most severe lesions due
to small number of such ﬁndings in our population. The
mean recomLine score was signiﬁcantly higher (p = 0 02) in
the group presenting with most severe lesions (5.7± 1.8)
compared to the mean score of H. pylori infected asymptom-
atic individuals (4.6± 1.9).
On the level of individual antigens, a signiﬁcant corre-
lation could be found between CagA or VacA and the
chronicity of inﬂammation (p = 0 015 or p < 0 01, respec-
tively), as well as CagA and the activity of inﬂammation
(p < 0 01) (Figure 3). The serological detection of the antigen
UreA tends to increase with disease severity. This, however,
was not signiﬁcant, possibly because of its overall low
prevalence in this setup. The antigens GroEL, HcpC, and
gGT are stable between the groups analysed (Supplementary
Table 3). Next, we looked for correlations between the indi-
vidual antigens and pathological ﬁndings, such as ulcer or
atrophy, metaplasia, and carcinoma. A signiﬁcant correla-
tion could again be seen for CagA (p < 0 01). Ulcer and
carcinoma cases also showed high seropositivity rates for
GroEL with 87.5% and 100%, respectively, but not at a signif-
icant correlation because of the high frequency in the control
group. A change in seropositivity could also be shown for the
antigen VacA, however not at a signiﬁcant level. Detailed
information is given in Supplementary Table 4.
The immune response towards a more virulent H. pylori
type I was deﬁned by CagA and/or VacA seropositivity and
towards the less virulent type II strains by a lack of immune
response towards CagA and VacA. Our data show a sig-
niﬁcant correlation between CagA seropositivity and clas-
siﬁcation of increasing pathology according to histology.
Therefore, a signiﬁcant correlation was also found for the
type of immune response to H. pylori. Here, we looked
at the 400 cases that were positive for H. pylori in histology
as well as by recomLine. Of these, 71.5% were H. pylori
type I and 28.5% type II, compared to 87.1% that were
classiﬁed as type I in the eradicated collective. As shown
in Figure 4, the proportion of type I immune response
signiﬁcantly increases with higher scores of chronicity or
activity of inﬂammation (p = 0 02 or p < 0 01, respectively).
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Figure 3: Association between positivity of individual antigens (●CagA, ■VacA, ▲GroEL, ▼UreA, ♦HcpC, and ○gGT) and histologic
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Furthermore, there is a signiﬁcant increase in the share of
type I immune response if signs of advanced pathology are
present in histology (p < 0 01), increasing up to a 100% type
I immune response in the gastric cancer group.
4. Discussion
H. pylori plays an important role in the development of
gastroduodenal diseases. Common serological methods for
the detection ofH. pylori do not allow distinguishing between
patients with an ongoing H. pylori infection and patients that
have received eradication therapy in the past. Furthermore,
these serological tests are not capable of stratifying patients
according to their individual disease state, even though
several virulence factors have been known for years. The
aim of the present study was to evaluate a new line assay
(recomLine) with respect to identifying individuals that have
received antibiotic treatment. Moreover, we evaluated the
capacity of the recomLine to stratify patients according to
their disease status. The present study conﬁrmed a high
sensitivity and speciﬁcity of 98.3% and 95.5%, respectively,
for the detection of an H. pylori infection by the recomLine
analysing this extended cohort. Nevertheless, serology still
plays a minor role in the standard diagnosis ofH. pylori, even
though studies have shown that serological screening for
H. pylori can reduce the endoscopy workload, which is
especially important in countries where access to endoscopy
is limited [28].
As our cohort includes a large proportion of individuals
that had received antibiotic treatment, we investigated the
behaviour of IgG immune responses after successfulH. pylori
eradication in this subpopulation. Current serological tests
are incapable of distinguishing an ongoing from a past H.
pylori infection. Histology as the gold standard in H. pylori
diagnosis may show an Ex-H. pylori gastritis after successful
eradication therapy, sometimes even after several decades.
However, after due course, the gastritis can also disappear
and previous H. pylori infection is indeterminable [29]. Fur-
thermore, the urea breath test only allows the identiﬁcation
of an ongoing infection. Thus, it might be helpful to employ
the recomLine to detect a past H. pylori infection. Our results
show that a low test score especially in combination with an
isolated CagA band may allow the diﬀerentiation of H. pylori
positive and eradicated individuals. The mean band intensity
and in parallel the immune response frequency decline after
successful H. pylori eradication for all antigens tested except
for CagA, which was particularly long lasting. Thus, this
decline in immune responses has an eﬀect on the test score
and the overall recomLine positivity. This was corroborated
in a prospective study, analysing a blinded Dutch cohort,
in which most of the cases turned out to have undergone
eradication therapy. Again, the results show a decrease in
immune response frequency for all antigens except for
CagA. In this cohort, the sensitivity of detecting a status
of prior eradication through an isolated CagA band would
increase up to 100% after 15 years. This study shows the
feasibility of detecting individuals that have received anti-
biotic treatment by analysing the immune responses to
individual antigens. One limitation of our study is that the
time span since eradication in most individuals was quite
long. For a more precise analysis, a prospective follow-up
study with known baseline antigen patterns should be con-
ducted, focusing on shorter time intervals. Furthermore,
IgA immune responses should be analysed to draw further
conclusions for this antibody class, as this class might be
more accurate to detect H. pylori pre- and postinfection as
suggested by Kato et al. [23].
In addition, we investigated whether or not the detection
of immune responses to individual antigens or the overall test
score might have the capacity to identify H. pylori positive
patients at increased disease risk, if the recomLine allows
the diﬀerentiation between the more virulent type I and the
more attenuated type II strains, and if this diﬀerentiation
might be associated with the disease outcome. The recomLine
test score, compared to the number of positive antigens,
shows a signiﬁcant correlation with the severity of gastritis
(activity and chronicity of inﬂammation) and most severe
lesions. The recomLine score was determined by assessing
the serological response to six H. pylori virulence factors
CagA, VacA, GroEL, UreA, HcpC, and gGT. 393 of the 400
recomLine positive cases were either CagA and/or GroEL
positive. The other four antigens were, thus, needed for
detecting those rare cases not being CagA/GroEL positive.
Moreover, they were valuable in the calculation of the
recomLine score, which was employed for the diﬀerentiation
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presence of an immune response against H. pylori virulence factors
CagA/VacA indicates a type I infection, and these are deﬁned as the
high-risk group. The chronicity and activity are categorized as mild,
moderate, and severe. Most severe lesions are categorized as absent,
atrophy, intestinal metaplasia, ulcer, and gastric cancer according
to histology. The proportion of type I immune response increases
with higher degrees of chronicity and activity of gastritis (p = 0 02
and p < 0 01, resp.). There is a signiﬁcant increase in the portion
of type I immune response if signs of advanced pathology are
present in histology (p < 0 01).
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between H. pylori positive and eradicated patients. In addi-
tion, we show a signiﬁcant correlation between the recomLine
score and the chronicity and activity of inﬂammation. The
more antigens were detected and, thus, the higher the recom-
Line scored, the more likely it was that the respective patient
presented with a severe gastritis. The highest recomLine
scores were found in patients with severe chronic and active
gastritis, as well as gastric or duodenal ulcer, and gastric
cancer patients. These patients were also more likely to have
a more virulent type I H. pylori infection. Thus, the recom-
Line test can identify patients at increased risk to present
with gastroduodenal disease and allows a further risk stratiﬁ-
cation concerning the pathogenicity of individual H. pylori
strains. Thus, the recomLine is the ﬁrst serologic test with
can support risk stratiﬁcation of H. pylori positive patients.
The more virulent H. pylori type I strains are in general
deﬁned through CagA positivity and secretion of “toxic”
VacA s1m1 [30]. Due to the relatively high homology
between the diﬀerent VacA forms and numerous shared
epitopes, serology cannot reliably diﬀerentiate the respective
proteins. A distinction between VacA s1m1 (the more
virulent form) and s2m2 (the more attenuated form) is not
possible with the current recomLine test. However, CagA
presence is mostly associated with the more virulent VacA
s1m1 form [15]. In total, 285 cases were either CagA or VacA
positive, the majority being CagA positive (97.5%). Only 7
cases were VacA positive but CagA negative, which were also
calculated as type I immune response. Future recomLine
optimization should enable the distinction in VacA positivity
according to its s and m variants in order to allow a more
accurate identiﬁcation of H. pylori type I strains.
Previously, it was reported that antibody responses
against GroEL correlate signiﬁcantly with disease outcome
[31]. In our study population, however, seroresponse against
GroEL showed no signiﬁcant correlation with increased
pathology, due to its high frequency in the control group. It
is known that GroEL has a high homology between H. pylori
isolates. Therefore, the diﬀerence between our ﬁndings
and published data might be due to antigen production,
or the test format applied, which might lead to alterations
in epitope recognition.
By identifying patients at increased disease risk, the
recomLine can help to reduce the number of patients needed
to treat and, thus, unnecessary side eﬀects of eradication
therapy are avoided. If in our study cohort only patients
who carry a more virulent type I H. pylori strain (according
to serology; n = 278) were to be treated in contrast to all H.
pylori positive patients (n = 400), 122 patients (30.5%) could
have been spared from probably unnecessary eradication
therapy. The 278 cases of type I immune response include
the majority of patients showing pathological ﬁndings in
histology: all (100%) gastric cancer cases, 87.5% (14/16) of
the gastric or duodenal ulcer cases (which would also be
identiﬁed through clinical symptoms), 88.7% (47/53) of
the metaplasia cases, 81.8% (18/22) of the atrophy cases,
85.0% (17/20) of the high activity of inﬂammation, and
89.3% (25/28) of the high chronicity of inﬂammation cases.
Thus, only 18 patients (12.7%) with such ﬁndings in histol-
ogy escaped recognition (10× score≥ 4; 8× score < 4). If only
patients with a type I immune response (n = 278) or a score
of 4 or higher (n = 58, type II immune response) were to be
treated, eight cases (5.6%) with pathological ﬁndings in his-
tology would not receive treatment (1× ulcer, 4× metaplasia,
1× atrophy, and 2× severe activity of inﬂammation). How-
ever, these patients might be subjected to further endoscopic
surveillance due to histological ﬁndings. Thus, the recomLine
supports the identiﬁcation of patients at higher risk. Never-
theless, histology still remains an important part of standard
diagnosis in order to identify all patients with severe gastritis
and changes in the gastric mucosa.
Serology by recomLine
Biopsy &
histology
Normal Pathology
Low risk
Negative
High risk+Risk factors
TherapySurveillance
Positive
No further measures
Figure 5: H. pylori diagnostic decision tree. Low risk: no seropositivity against CagA and VacA and no additional risk factors; +Risk factors:
no seropositivity against CagA and VacA but additional risk factors such as smoking, diet, and genetic predisposition; High risk:
seropositivity against CagA and VacA.
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Our patients showed a high frequency of type I immune
responses in the H. pylori positive collective (71.5%). As
already mentioned, patients with severe gastritis, metaplasia,
ulcer, and carcinoma showed high type I rates. However,
patients with already a mild gastritis showed high rates of
CagA positivity in both cohorts (61% and 65%, respectively).
These patients might be at an early stage of their disease and
thus at a milder level of inﬂammation, as the mean age of
these patients (mild chronic and active inﬂammation and
a type I immune response) was 53.9 (±14.6), compared
to a mean age of 63.0 (±13.1) in patients with high chro-
nicity and highly active gastritis. Further longitudinal stud-
ies are needed in order to assess disease development in
such a group compared to a reference group of type II
immune response patients in order to validate such prog-
nostic patient stratiﬁcation.
To further evaluate the predictive properties of the
recomLine, a larger patient collective has to be screened, as
the present cohort included only a minority of advanced
stages of gastric disease. Moreover, the inclusion of addi-
tional antigens may provide further information concerning
the pathogenicity of H. pylori. Especially, the discrimination
between a type I and type II immune response needs to be
further substantiated, for example, by distinguishing sero-
positivity of the more virulent VacA s1m1 from the s2m2
variant or by identifying new biomarkers.
We conclude that the recomLine is a sensitive, speciﬁc,
and noninvasive test for the detection of the serum response
to an H. pylori infection. Moreover, this assay has indicative
capacity to identify patients at higher risk for H. pylori
associated diseases. We, therefore, propose to include recom-
Line-based serology in the clinical handling ofH. pylori infec-
tion according to the decision tree as suggested in Figure 5.We
are aware that the practical implementation in the clinical
practice presents a challenge for such test. As withmany novel
diagnostic tools, it may take years to incorporate them into
clinical guidelines. Yet, since the ﬁrst presentation of our data
on scientiﬁcmeetings, several gastroenterologists in Germany
have started to use the line blot as an additional means to
assess the putative disease risk of H. pylori-infected patients
presenting with chronic gastritis. Clinical trials investigating
the usefulness of such test in a prospectivemanner (i.e., before
endoscopy is performed) are underway andmay help to intro-
duce the test into clinical practice. Further, we are currently
performing cost-eﬃciency calculations of the algorithm pro-
posed in Figure 5 to substantiate the advantages of such
approach. Thus, the recomLine assay could present a valuable
tool for an easy-to-perform, cost-eﬀective primary patient
screen, and could help to identify patients who require endo-
scopic evaluation and subsequent antibiotic therapy.
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